{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:29:44Z","timestamp":1790364584921,"version":"4.1.0"},"reference-count":165,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Chronic kidney disease (CKD) represents a major global public health challenge, significantly impacting patients\u2019 quality of life and placing a heavy burden on healthcare systems. While diabetes and hypertension are the primary risk factors for CKD, non-diabetic CKD also constitutes a significant proportion, with its complex pathological mechanisms necessitating the development of novel therapeutic strategies. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors, initially developed for diabetes management, have recently demonstrated remarkable renal and cardiovascular protective effects in patients with non-diabetic CKD. SGLT-2 inhibitors exert their effects through multiple mechanisms, including reactivating the tubulo-glomerular feedback, reducing glomerular pressure and filtration rate, decreasing proteinuria, inhibiting inflammation and fibrosis, and improving systemic metabolic parameters such as lowering blood pressure, uric acid levels, and body weight. These effects not only slow the progression of kidney function decline but also significantly reduce the risk of end-stage renal disease (ESRD) and cardiovascular events. Landmark clinical trials such as DAPA-CKD, CREDENCE, and EMPA-KIDNEY provide strong scientific evidence supporting the use of SGLT-2 inhibitors in non-diabetic CKD, demonstrating their broad clinical benefits and excellent safety profile. Despite potential adverse effects such as urinary tract infections, hypotension, and diabetic ketoacidosis, appropriate patient selection and personalized treatment strategies can effectively manage these risks. The multi-system effects of SGLT-2 inhibitors not only expand their clinical indications but also offer new hope for the comprehensive management of non-diabetic CKD patients, with significant clinical implications and broad future application potential.<\/jats:p>","DOI":"10.3389\/fmed.2025.1574693","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T05:28:49Z","timestamp":1751347729000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Application of SGLT-2 inhibitors in non-diabetic CKD: mechanisms, efficacy, and safety"],"prefix":"10.3389","volume":"12","author":[{"given":"Bing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liufei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","article-title":"Chronic kidney disease and the global public health agenda: an international consensus","volume":"20","author":"Francis","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s11606-010-1511-x","article-title":"Chronic kidney disease and the risk of end-stage renal disease versus death","volume":"26","author":"Dalrymple","year":"2011","journal-title":"J Gen Intern Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e101061","DOI":"10.5812\/ijem.101061","article-title":"Diabetes, hypertension, and incidence of chronic kidney disease: is there any multiplicative or additive interaction?","volume":"19","author":"Erfanpoor","year":"2021","journal-title":"Int J Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1093\/ckj\/sfx111","article-title":"Clinical and pathological characteristics of non-diabetic renal disease in type 2 diabetes patients","volume":"11","author":"Kritmetapak","year":"2018","journal-title":"Clin Kidney J"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"10848","DOI":"10.1021\/acs.jmedchem.2c00867","article-title":"Sodium-glucose cotransporter inhibitors as antidiabetic drugs: current development and future perspectives","volume":"65","author":"Maccari","year":"2022","journal-title":"J Med Chem"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/MNH.0000000000000187","article-title":"Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update","volume":"25","author":"Novikov","year":"2016","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1007\/s11255-023-03586-1","article-title":"The efficacy and safety of SGLT2 inhibitors in patients with non-diabetic chronic kidney disease: a systematic review and meta-analysis","volume":"55","author":"Ma","year":"2023","journal-title":"Int Urol Nephrol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/14779072.2022.2057949","article-title":"Beneficial cardiovascular and remodeling effects of SGLT 2 inhibitors","volume":"20","author":"Chrysant","year":"2022","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2213-8587(21)00242-4","article-title":"Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Heerspink","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1388665","DOI":"10.3389\/fmed.2024.1388665","article-title":"Chronic kidney diseases and inflammation research: a bibliometric analysis","volume":"11","author":"Wang","year":"2024","journal-title":"Front Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/ckj\/sfaa198","article-title":"SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia","volume":"13","author":"Fernandez-Fernandez","year":"2020","journal-title":"Clin Kidney J"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1080\/00325481.2024.2418795","article-title":"SGLT2 inhibitors across the spectrum of chronic kidney disease: a narrative review","volume":"136","author":"Sloan","year":"2024","journal-title":"Postgrad Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1213473","DOI":"10.3389\/fimmu.2023.1213473","article-title":"Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease","volume":"14","author":"Dai","year":"2023","journal-title":"Front Immunol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2215\/CJN.09380822","article-title":"Kidney-protective effects of SGLT2 inhibitors","volume":"18","author":"Palmer","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s11302-023-09973-8","article-title":"Modafinil exerts anti-inflammatory and anti-fibrotic effects by upregulating adenosine a(2A) and a(2B) receptors","volume":"20","author":"Li","year":"2024","journal-title":"Purinergic Signal"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.drudis.2009.03.012","article-title":"Synergistic therapeutic actions of herbal ingredients and their mechanisms from molecular interaction and network perspectives","volume":"14","author":"Ma","year":"2009","journal-title":"Drug Discov Today"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/ndt\/gfae027","article-title":"Glomerular hyperfiltration as a therapeutic target for CKD","volume":"39","author":"Kanbay","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"676","DOI":"10.2215\/CJN.12391213","article-title":"Integrated control of Na transport along the nephron","volume":"10","author":"Palmer","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"S383","DOI":"10.1097\/00005344-198406002-00013","article-title":"The afferent glomerular arteriole: immunocytochemical and electrophysiological investigations","volume":"6","author":"B\u00fchrle","year":"1984","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/HYPERTENSIONAHA.119.11684","article-title":"Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors","volume":"75","author":"Wilcox","year":"2020","journal-title":"Hypertension"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00467-016-3358-9","article-title":"Mechanical challenges to the glomerular filtration barrier: adaptations and pathway to sclerosis","volume":"32","author":"Kriz","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s12325-021-01994-2","article-title":"Chronic kidney disease and SGLT2 inhibitors: a review of the evolving treatment landscape","volume":"39","author":"Mende","year":"2022","journal-title":"Adv Ther"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.trre.2011.10.002","article-title":"Proteinuria: detection and role in native renal disease progression","volume":"26","author":"Gorriz","year":"2012","journal-title":"Transplant Rev (Orlando)"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.yexcr.2012.02.031","article-title":"The glomerular basement membrane","volume":"318","author":"Miner","year":"2012","journal-title":"Exp Cell Res"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1159\/000161982","article-title":"The molecular interactions between filtered proteins and proximal tubular cells in proteinuria","volume":"110","author":"Baines","year":"2008","journal-title":"Nephron Exp Nephrol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/ajh\/hpae092","article-title":"State-of-the-art-review: mechanisms of action of SGLT2 inhibitors and clinical implications","volume":"37","author":"Vallon","year":"2024","journal-title":"Am J Hypertens"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S2213-8587(20)30162-5","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial","volume":"8","author":"Cherney","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus","volume":"75","author":"Scheen","year":"2015","journal-title":"Drugs"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"113614","DOI":"10.1016\/j.yexcr.2023.113614","article-title":"AMP-activated protein kinase: an energy sensor and survival mechanism in the reinstatement of metabolic homeostasis","volume":"428","author":"Sharma","year":"2023","journal-title":"Exp Cell Res"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.molcel.2017.05.032","article-title":"AMPK: mechanisms of cellular energy sensing and restoration of metabolic balance","volume":"66","author":"Garcia","year":"2017","journal-title":"Mol Cell"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.2337\/db12-0052","article-title":"Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?","volume":"61","author":"Liu","year":"2012","journal-title":"Diabetes"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2337\/db14-0582","article-title":"Regulation of AMPK activation by CD36 links fatty acid uptake to \u03b2-oxidation","volume":"64","author":"Samovski","year":"2015","journal-title":"Diabetes"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1163288","DOI":"10.3389\/fimmu.2023.1163288","article-title":"GLP-1 RAs and SGLT2i: two antidiabetic agents associated with immune and inflammation modulatory properties through the common AMPK pathway","volume":"14","author":"Mazzieri","year":"2023","journal-title":"Front Immunol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1053\/j.ajkd.2020.04.016","article-title":"Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: modulation by SGLT2 inhibitors and hypoxia Mimetics","volume":"77","author":"Packer","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"105742","DOI":"10.1016\/j.phrs.2021.105742","article-title":"Hypoxia-inducible factor-1: regulatory mechanisms and drug development in stroke","volume":"170","author":"Pan","year":"2021","journal-title":"Pharmacol Res"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3779\/j.issn.1009-3419.2007.06.13","article-title":"The relationship of expression of GLUT1,HIF-1\u03b1 and the uptake of FDG in non-small cell lung cancer","volume":"10","author":"Ai","year":"2007","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3109\/08977194.2011.595714","article-title":"TGF-\u03b2 signaling in fibrosis","volume":"29","author":"Biernacka","year":"2011","journal-title":"Growth Factors"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1097\/HJH.0000000000002050","article-title":"The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Piperidou","year":"2019","journal-title":"J Hypertens"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1124\/mol.115.099549","article-title":"AMPK inhibits the stimulatory effects of TGF-\u03b2 on Smad2\/3 activity, cell migration, and epithelial-to-mesenchymal transition","volume":"88","author":"Lin","year":"2015","journal-title":"Mol Pharmacol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.tcb.2012.08.001","article-title":"The nuclear factor kappa B signaling pathway: integrating metabolism with inflammation","volume":"22","author":"Tornatore","year":"2012","journal-title":"Trends Cell Biol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"729384","DOI":"10.3389\/fphar.2021.729384","article-title":"Berberine reduces lipid accumulation by promoting fatty acid oxidation in renal tubular epithelial cells of the diabetic kidney","volume":"12","author":"Rong","year":"2021","journal-title":"Front Pharmacol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrm2083","article-title":"Integrating cell-signalling pathways with NF-kappaB and IKK function","volume":"8","author":"Perkins","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1042\/CS20210094","article-title":"Angiotensin II up-regulates sodium-glucose co-transporter 2 expression and SGLT2 inhibitor attenuates Ang II-induced hypertensive renal injury in mice","volume":"135","author":"Miyata","year":"2021","journal-title":"Clin Sci"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1463-1326.2008.00982.x","article-title":"Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug","volume":"11","author":"Idris","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1161\/HYPERTENSIONAHA.117.10357","article-title":"Angiotensin II short-loop feedback: is there a role of Ang II for the regulation of the renin system in vivo?","volume":"71","author":"Neubauer","year":"2018","journal-title":"Hypertension"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/08037050310001057","article-title":"Angiotensin AT1\/AT2 receptors: regulation, signalling and function","volume":"12","author":"Kaschina","year":"2003","journal-title":"Blood Press"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"e29486","DOI":"10.1016\/j.heliyon.2024.e29486","article-title":"SGLT-2 inhibitors as novel treatments of multiple organ fibrosis","volume":"10","author":"Hu","year":"2024","journal-title":"Heliyon"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the Cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000368940","article-title":"Update on inflammation in chronic kidney disease","volume":"39","author":"Akchurin","year":"2015","journal-title":"Blood Purif"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"102524","DOI":"10.1016\/j.cpcardiol.2024.102524","article-title":"Targeting inflammatory signaling pathways with SGLT2 inhibitors: insights into cardiovascular health and cardiac cell improvement","volume":"49","author":"Alsereidi","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1007\/s40618-023-02162-9","article-title":"The anti-inflammatory and immunological properties of SGLT-2 inhibitors","volume":"46","author":"Bendotti","year":"2023","journal-title":"J Endocrinol Investig"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13098-024-01325-9","article-title":"Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus","volume":"16","author":"Zhang","year":"2024","journal-title":"Diabetol Metab Syndr"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/sj.ki.5000054","article-title":"Renal fibrosis: new insights into the pathogenesis and therapeutics","volume":"69","author":"Liu","year":"2006","journal-title":"Kidney Int"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"110072","DOI":"10.1016\/j.intimp.2023.110072","article-title":"New insights into the molecular mechanisms of SGLT2 inhibitors on ventricular remodeling","volume":"118","author":"Chen","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41392-023-01379-7","article-title":"Kidney fibrosis: from mechanisms to therapeutic medicines","volume":"8","author":"Huang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12933-020-01071-y","article-title":"SGLT2i: beyond the glucose-lowering effect","volume":"19","author":"Ni","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s11906-023-01281-1","article-title":"Blood pressure effects of SGLT2 inhibitors: mechanisms and clinical evidence in different populations","volume":"25","author":"Beal","year":"2023","journal-title":"Curr Hypertens Rep"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41371-020-00393-4","article-title":"SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives","volume":"35","author":"Piperidou","year":"2021","journal-title":"J Hum Hypertens"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/bdd.1909","article-title":"SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria","volume":"35","author":"Chino","year":"2014","journal-title":"Biopharm Drug Dispos"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/dom.13670","article-title":"Uric acid and the cardio-renal effects of SGLT2 inhibitors","volume":"21","author":"Bailey","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/oby.23331","article-title":"SGLT inhibitors on weight and body mass: a meta-analysis of 116 randomized-controlled trials","volume":"30","author":"Cheong","year":"2022","journal-title":"Obesity (Silver Spring)"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/obr.12841","article-title":"Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: mechanistic possibilities","volume":"20","author":"Brown","year":"2019","journal-title":"Obes Rev"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1053\/j.ajkd.2024.06.011","article-title":"Symptom burden and its impact on quality of life in patients with moderate to severe CKD: the international chronic kidney disease outcomes and practice patterns study (CKDopps)","volume":"84","author":"Speyer","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.sjbs.2021.01.010","article-title":"Effect of social media use on learning, social interactions, and sleep duration among university students","volume":"28","author":"Kolhar","year":"2021","journal-title":"Saudi J Biol Sci"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1515\/jom-2020-0153","article-title":"SGLT2 inhibitors: a narrative review of efficacy and safety","volume":"121","author":"Nelinson","year":"2021","journal-title":"J Osteopath Med"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3389\/fendo.2019.00441","article-title":"Dapagliflozin attenuates renal Tubulointerstitial fibrosis associated with type 1 diabetes by regulating STAT1\/TGF\u03b21 signaling","volume":"10","author":"Huang","year":"2019","journal-title":"Front Endocrinol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1080\/14656566.2017.1300253","article-title":"Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes","volume":"18","author":"Fioretto","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jacc.2024.02.009","article-title":"Efficacy and safety of Dapagliflozin in patients with acute heart failure","volume":"83","author":"Cox","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.ekir.2022.01.1071","article-title":"Efficacy and safety of Dapagliflozin in patients with CKD across major geographic regions","volume":"7","author":"Vart","year":"2022","journal-title":"Kidney Int Rep"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"15922","DOI":"10.1038\/s41598-023-42999-9","article-title":"SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis","volume":"13","author":"Mavrakanas","year":"2023","journal-title":"Sci Rep"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/jdi.13389","article-title":"Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise","volume":"12","author":"Ji","year":"2021","journal-title":"J Diabetes Investig"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"101158","DOI":"10.1016\/j.molmet.2020.101158","article-title":"Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: a step toward personalised diabetes treatment?","volume":"46","author":"Veelen","year":"2021","journal-title":"Mol Metab"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.2215\/CJN.10140620","article-title":"Effects of Canagliflozin in patients with baseline eGFR <30 ml\/min per 1.73 m(2): subgroup analysis of the randomized CREDENCE trial","volume":"15","author":"Bakris","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1111\/dom.14376","article-title":"The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: analysis of the CREDENCE trial","volume":"23","author":"Arnott","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1053\/j.ajkd.2021.05.005","article-title":"Canagliflozin and kidney-related adverse events in type 2 diabetes and CKD: findings from the randomized CREDENCE trial","volume":"79","author":"Heerspink","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"ref80","article-title":"Long-term effects of Empagliflozin in patients with chronic kidney disease","author":"Herrington","year":"2024","journal-title":"N Engl J Med"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/ndt\/gfac040","article-title":"Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial","volume":"37","author":"Thomas","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/jcpt.13521","article-title":"Efficacy and safety of empagliflozin at different doses in patients with type 2 diabetes mellitus: a network meta-analysis based on randomized controlled trials","volume":"47","author":"Wu","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(23)00322-4","article-title":"Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial","volume":"12","author":"George","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.2174\/0929867329666220825121304","article-title":"SGLT-2 inhibitors and Nephroprotection in patients with diabetic and non-diabetic chronic kidney disease","volume":"30","author":"Sarafidis","year":"2023","journal-title":"Curr Med Chem"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1001\/jama.2014.6634","article-title":"Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality","volume":"311","author":"Coresh","year":"2014","journal-title":"JAMA"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s43440-022-00442-4","article-title":"Sodium-glucose cotransporter inhibitors and kidney fibrosis: review of the current evidence and related mechanisms","volume":"75","author":"Afsar","year":"2023","journal-title":"Pharmacol Rep"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"106659","DOI":"10.1016\/j.phrs.2023.106659","article-title":"Dapagliflozin protects the kidney in a non-diabetic model of cardiorenal syndrome","volume":"188","author":"Urbanek","year":"2023","journal-title":"Pharmacol Res"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"e15092","DOI":"10.14814\/phy2.15092","article-title":"SGLT-1-specific inhibition ameliorates renal failure and alters the gut microbial community in mice with adenine-induced renal failure","volume":"9","author":"Ho","year":"2021","journal-title":"Physiol Rep"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.3390\/medicina60111821","article-title":"Proteinuria and progression of renal damage: the Main Pathogenetic mechanisms and pharmacological approach","volume":"60","author":"Longhitano","year":"2024","journal-title":"Medicina"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.2337\/dc22-0921","article-title":"Activation of the Tubulo-glomerular feedback by SGLT2 inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: toward the end of a myth?","volume":"45","author":"G\u00e9rard","year":"2022","journal-title":"Diabetes Care"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/MNH.0000000000000584","article-title":"Renal effects of SGLT2 inhibitors: an update","volume":"29","author":"Nespoux","year":"2020","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1016\/j.ekir.2022.09.021","article-title":"Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations","volume":"7","author":"Yau","year":"2022","journal-title":"Kidney Int Rep"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1056\/NEJMc2118470","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"386","author":"Anker","year":"2022","journal-title":"Reply"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ijcard.2021.10.033","article-title":"Effects of SGLT-2 inhibitors on health-related quality of life and exercise capacity in heart failure patients with reduced ejection fraction: a systematic review and meta-analysis","volume":"345","author":"He","year":"2021","journal-title":"Int J Cardiol"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph192114549","article-title":"The quality of life and medication adherence in patients with multiple sclerosis-cross-sectional study","volume":"19","author":"Ko\u0142tuniuk","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.2215\/CJN.19891220","article-title":"Fatigue in CKD: epidemiology, pathophysiology, and treatment","volume":"16","author":"Gregg","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40256-024-00673-1","article-title":"SGLT2 inhibitors and how they work beyond the Glucosuric effect. State of the art","volume":"24","author":"Aristiz\u00e1bal-Colorado","year":"2024","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref100","first-page":"121","article-title":"The importance of daily physical activity for improved exercise tolerance in heart failure patients with limited access to Centre-based cardiac rehabilitation","volume":"17","author":"Sato","year":"2012","journal-title":"Exp Clin Cardiol"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12933-023-02081-2","article-title":"Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis","volume":"23","author":"Chen","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10741-020-10038-w","article-title":"SGLT2-inhibitors; more than just glycosuria and diuresis","volume":"26","author":"Fathi","year":"2021","journal-title":"Heart Fail Rev"},{"key":"ref103","article-title":"The effects of SGLT2 inhibitors on lipid metabolism","volume":"11","author":"Szekeres","year":"2021","journal-title":"Meta"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12933-023-02035-8","article-title":"Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis","volume":"22","author":"Chen","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10092036","article-title":"SGLT2 inhibitors, what the emergency physician needs to know: a narrative review","volume":"10","author":"Lu","year":"2021","journal-title":"J Clin Med"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1038\/s41467-021-23439-8","article-title":"A distinct growth physiology enhances bacterial growth under rapid nutrient fluctuations","volume":"12","author":"Nguyen","year":"2021","journal-title":"Nat Commun"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"270","DOI":"10.62438\/tunismed.v103i2.5020","article-title":"Not Available","volume":"103","author":"Marzouk","year":"2025","journal-title":"Tunis Med"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"11795514241312849","DOI":"10.1177\/11795514241312849","article-title":"Diabetic ketoacidosis in pregnancy: a systematic review of the reported cases","volume":"18","author":"Stathi","year":"2025","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s40265-021-01573-3","article-title":"A role for SGLT-2 inhibitors in treating non-diabetic chronic kidney disease","volume":"81","author":"Del Vecchio","year":"2021","journal-title":"Drugs"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"14379","DOI":"10.1074\/jbc.REV120.008387","article-title":"Sodium-glucose cotransporter-2 inhibitors: understanding the mechanisms for therapeutic promise and persisting risks","volume":"295","author":"Perry","year":"2020","journal-title":"J Biol Chem"},{"key":"ref111","article-title":"The effect of digital therapeutics intervention on improving hypertension management in adults: a meta-analysis of randomized controlled trial","author":"Liu","year":"2024","journal-title":"Hypertens Res"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.amjmed.2007.02.023","article-title":"Orthostatic hypotension in the elderly: diagnosis and treatment","volume":"120","author":"Gupta","year":"2007","journal-title":"Am J Med"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1089\/met.2015.0038","article-title":"The use of SGLT-2 inhibitors in type 2 diabetes and heart failure","volume":"13","author":"Riggs","year":"2015","journal-title":"Metab Syndr Relat Disord"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.euf.2016.08.006","article-title":"Urinary tract infections in immunocompromised patients with diabetes, chronic kidney disease, and kidney transplant","volume":"2","author":"Tandogdu","year":"2016","journal-title":"Eur Urol Focus"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.bja.2023.11.015","article-title":"Sodium-glucose cotransporter-2 inhibitors in non-diabetic patients: is there a perioperative risk of euglycaemic ketoacidosis","volume":"132","author":"Ruste","year":"2024","journal-title":"Br J Anaesth"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"683","DOI":"10.4239\/wjd.v13.i9.683","article-title":"A review of potential mechanisms and uses of SGLT2 inhibitors in ischemia-reperfusion phenomena","volume":"13","author":"Quentin","year":"2022","journal-title":"World J Diabetes"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"6852","DOI":"10.61186\/ajtr.v16i11.144","article-title":"Efficacy and safety of GLP-1 receptor agonists combined with SGLT-2 inhibitors in elderly patients with type 2 diabetes: a meta-analysis","volume":"16","author":"Wu","year":"2024","journal-title":"Am J Transl Res"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"101285","DOI":"10.1016\/j.diabet.2021.101285","article-title":"The diuretic effects of SGLT2 inhibitors: a comprehensive review of their specificities and their role in renal protection","volume":"47","author":"Delanaye","year":"2021","journal-title":"Diabetes Metab"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"5564","DOI":"10.2174\/0929867326666190722100829","article-title":"SGLT-2 inhibitors in diabetic kidney disease: what lies behind their Renoprotective properties?","volume":"26","author":"Georgianos","year":"2019","journal-title":"Curr Med Chem"},{"key":"ref120","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/ckj\/sfad025","article-title":"Immune abnormalities in IgA nephropathy","volume":"16","author":"Gentile","year":"2023","journal-title":"Clin Kidney J"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/nrneph.2012.191","article-title":"The role of the kidney in regulating arterial blood pressure","volume":"8","author":"Wadei","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1006\/mgme.1999.2896","article-title":"Somatic mutation as mechanism for cyst formation in autosomal dominant polycystic kidney disease","volume":"68","author":"Qian","year":"1999","journal-title":"Mol Genet Metab"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"502","DOI":"10.2215\/CJN.05960616","article-title":"Focal Segmental Glomerulosclerosis","volume":"12","author":"Rosenberg","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"e15836","DOI":"10.14814\/phy2.15836","article-title":"Modeling the renoprotective mechanisms of SGLT2 inhibition in hypertensive chronic kidney disease","volume":"11","author":"Clemmer","year":"2023","journal-title":"Physiol Rep"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"ref126","doi-asserted-by":"crossref","first-page":"e614","DOI":"10.1002\/mco2.614","article-title":"Membranous nephropathy: pathogenesis and treatments","volume":"5","author":"Wang","year":"2020","journal-title":"MedComm"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00467-016-3394-5","article-title":"Tubulointerstitial nephritis: diagnosis, treatment, and monitoring","volume":"32","author":"Joyce","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"ref128","doi-asserted-by":"crossref","first-page":"108634","DOI":"10.1016\/j.jnutbio.2021.108634","article-title":"Dietary polyphenols suppress chronic inflammation by modulation of multiple inflammation-associated cell signaling pathways","volume":"93","author":"Jantan","year":"2021","journal-title":"J Nutr Biochem"},{"key":"ref129","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kisu.2020.12.006","article-title":"Treatment of anemia in difficult-to-manage patients with chronic kidney disease","volume":"11","author":"Raichoudhury","year":"2021","journal-title":"Kidney Int Suppl"},{"key":"ref130","doi-asserted-by":"crossref","first-page":"110192","DOI":"10.1016\/j.biopha.2020.110192","article-title":"Combination therapy with SGLT2 inhibitors for diabetic kidney disease","volume":"127","author":"Cai","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"105859","DOI":"10.1016\/j.phrs.2021.105859","article-title":"Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - new perspectives for combination therapy","volume":"172","author":"Kolkhof","year":"2021","journal-title":"Pharmacol Res"},{"key":"ref132","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1161\/HYPERTENSIONAHA.109.134973","article-title":"Mineralocorticoid and glucocorticoid receptors stimulate epithelial sodium channel activity in a mouse model of Cushing syndrome","volume":"54","author":"Bailey","year":"2009","journal-title":"Hypertension"},{"key":"ref133","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1038\/sj.jhh.1000991","article-title":"Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension","volume":"14","author":"Israili","year":"2000","journal-title":"J Hum Hypertens"},{"key":"ref134","doi-asserted-by":"publisher","first-page":"23102","DOI":"10.18632\/oncotarget.24562","article-title":"A targeted transforming growth factor-beta (TGF-\u03b2) blocker, TTB, inhibits tumor growth and metastasis","volume":"9","author":"Zhou","year":"2018","journal-title":"Oncotarget"},{"key":"ref135","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11892-021-01442-z","article-title":"Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease","volume":"22","author":"Bailey","year":"2022","journal-title":"Curr Diab Rep"},{"key":"ref136","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.3390\/biomedicines11072085","article-title":"Cardiovascular diseases: therapeutic potential of SGLT-2 inhibitors","volume":"11","author":"Fr\u0105k","year":"2023","journal-title":"Biomedicines"},{"key":"ref137","doi-asserted-by":"publisher","first-page":"F824","DOI":"10.1152\/ajprenal.00314.2017","article-title":"Canagliflozin reduces plasma uremic toxins and alters the intestinal microbiota composition in a chronic kidney disease mouse model","volume":"315","author":"Mishima","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref138","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3390\/toxins14030210","article-title":"Effects of an SGLT inhibitor on the production, toxicity, and elimination of gut-derived uremic toxins: a call for additional evidence","volume":"14","author":"Evenepoel","year":"2022","journal-title":"Toxins"},{"key":"ref139","doi-asserted-by":"publisher","first-page":"C994","DOI":"10.1152\/ajpcell.00367.2024","article-title":"Renoprotective effects of empagliflozin in high-fat diet-induced obesity-related glomerulopathy by regulation of gut-kidney axis","volume":"327","author":"Lei","year":"2024","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref140","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11886-022-01637-0","article-title":"SGLT2 inhibitors: benefits for CKD and cardiovascular disease in type 2 diabetes","volume":"24","author":"Singhal","year":"2022","journal-title":"Curr Cardiol Rep"},{"key":"ref141","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1159\/000530395","article-title":"Efficacy and safety of sodium-glucose Cotransporter-2 inhibitors in nondiabetic patients with chronic kidney disease: a review of recent evidence","volume":"9","author":"Lv","year":"2023","journal-title":"Kidney Dis"},{"key":"ref142","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/2040622317735283","article-title":"Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential","volume":"9","author":"R\u00f8der","year":"2018","journal-title":"Ther Adv Chronic Dis"},{"key":"ref143","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-025-01476-z","article-title":"Cardiorenal syndrome: clinical diagnosis, molecular mechanisms and therapeutic strategies","author":"Zhao","year":"2025","journal-title":"Acta Pharmacol Sin"},{"key":"ref144","article-title":"Crucial role for sodium hydrogen exchangers in SGLT2 inhibitor-induced arterial relaxations","author":"Forrester","year":"2023","journal-title":"bioRxiv"},{"key":"ref145","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"ref146","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"ref147","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2023-003836","article-title":"Effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on serum uric acid levels in patients with chronic kidney disease: a systematic review and network meta-analysis","volume":"12","author":"Zhang","year":"2024","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref148","doi-asserted-by":"publisher","first-page":"777861","DOI":"10.3389\/fmed.2021.777861","article-title":"Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review","volume":"8","author":"Fonseca-Correa","year":"2021","journal-title":"Front Med"},{"key":"ref149","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1159\/000533537","article-title":"Altered intestinal microbial Flora and Metabolism in patients with idiopathic membranous nephropathy","volume":"54","author":"Shi","year":"2023","journal-title":"Am J Nephrol"},{"key":"ref150","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s00018-024-05532-5","article-title":"Gut microbiota regulates oxidative stress and inflammation: a double-edged sword in renal fibrosis","volume":"81","author":"Li","year":"2024","journal-title":"Cell Mol Life Sci"},{"key":"ref151","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1038\/s41401-023-01056-5","article-title":"Serum granulosa cell-derived TNF-\u03b1 promotes inflammation and apoptosis of renal tubular cells and PCOS-related kidney injury through NF-\u03baB signaling","volume":"44","author":"Ye","year":"2023","journal-title":"Acta Pharmacol Sin"},{"key":"ref152","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/bph.16219","article-title":"Targeting Lactobacillus johnsonii to reverse chronic kidney disease","volume":"9","author":"Miao","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"ref153","doi-asserted-by":"crossref","first-page":"112169","DOI":"10.1016\/j.biopha.2021.112169","article-title":"Effects of SGLT2 inhibitors on ion homeostasis and oxidative stress associated mechanisms in heart failure","volume":"143","author":"Gager","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"ref154","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41401-023-01148-w","article-title":"Sirtuin 6 protects against podocyte injury by blocking the renin-angiotensin system by inhibiting the Wnt1\/\u03b2-catenin pathway","volume":"45","author":"Miao","year":"2024","journal-title":"Acta Pharmacol Sin"},{"key":"ref155","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/bph.16219","article-title":"Lactobacillus species ameliorate membranous nephropathy through inhibiting the aryl hydrocarbon receptor pathway via tryptophan-produced indole metabolites","volume":"181","author":"Miao","year":"2024","journal-title":"Br J Pharmacol"},{"key":"ref156","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/jcpt.13385","article-title":"Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: a meta-analysis including 13,146 patients","volume":"46","author":"Chen","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"ref157","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.pedneo.2022.07.005","article-title":"The pathological spectrum of pediatric kidney disease: 18-year experience from a single tertiary care center in northern Taiwan","volume":"64","author":"Yen","year":"2023","journal-title":"Pediatr Neonatol"},{"key":"ref158","doi-asserted-by":"publisher","first-page":"1302352","DOI":"10.3389\/fmed.2023.1302352","article-title":"Specific gut microbiome and metabolome changes in patients with continuous ambulatory peritoneal dialysis and comparison between patients with different dialysis vintages","volume":"10","author":"Li","year":"2023","journal-title":"Front Med"},{"key":"ref159","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41581-024-00854-w","article-title":"Treatment of chronic kidney disease in older populations","volume":"20","author":"Kishi","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"ref160","doi-asserted-by":"publisher","first-page":"97214","DOI":"10.5527\/wjn.v13.i3.97214","article-title":"Challenges in predictive modelling of chronic kidney disease: a narrative review","volume":"13","author":"Khandpur","year":"2024","journal-title":"World J Nephrol"},{"key":"ref161","doi-asserted-by":"crossref","DOI":"10.3390\/antiox10081166","article-title":"Emergence of SGLT2 inhibitors as powerful antioxidants in human diseases","volume":"10","author":"Tsai","year":"2021","journal-title":"Antioxidants"},{"key":"ref162","doi-asserted-by":"crossref","first-page":"1309582","DOI":"10.3389\/fphar.2023.1309582","article-title":"Renal and survival benefits of seventeen prescribed Chinese herbal medicines against oxidative-inflammatory stress in systemic lupus erythematosus patients with chronic kidney disease: a real-world longitudinal study","volume":"14","author":"Chen","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref163","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/nep.14167","article-title":"Practical considerations for the use of SGLT-2 inhibitors in the Asia-Pacific countries-an expert consensus statement","volume":"28","author":"Liew","year":"2023","journal-title":"Nephrology (Carlton)"},{"key":"ref164","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1111\/tmi.13651","article-title":"What factors affect patients' ability to access healthcare? An overview of systematic reviews","volume":"26","author":"Dawkins","year":"2021","journal-title":"Trop Med Int Health"},{"key":"ref165","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.drudis.2015.11.009","article-title":"Extensions of indication throughout the drug product lifecycle: a quantitative analysis","volume":"21","author":"Langedijk","year":"2016","journal-title":"Drug Discov Today"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1574693\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T05:28:54Z","timestamp":1751347734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1574693\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":165,"alternative-id":["10.3389\/fmed.2025.1574693"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1574693","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"article-number":"1574693"}}